EA200800943A1 - MODULATION OF TLR-MEDIATED IMMUNE RESPONSES WITH THE USE OF OLIGONUCLEOTIDE ADAPTERS - Google Patents

MODULATION OF TLR-MEDIATED IMMUNE RESPONSES WITH THE USE OF OLIGONUCLEOTIDE ADAPTERS

Info

Publication number
EA200800943A1
EA200800943A1 EA200800943A EA200800943A EA200800943A1 EA 200800943 A1 EA200800943 A1 EA 200800943A1 EA 200800943 A EA200800943 A EA 200800943A EA 200800943 A EA200800943 A EA 200800943A EA 200800943 A1 EA200800943 A1 EA 200800943A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tlr
modulation
immune responses
mediated immune
oligonucleotide adapters
Prior art date
Application number
EA200800943A
Other languages
Russian (ru)
Inventor
Марион Юрк
Йорг Фолльмер
Артур М. Криг
Ойген Ульманн
Бернхард О. Нолль
Original Assignee
Коли Фармасьютикал Гмбх
Коли Фармасьютикал Груп, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Коли Фармасьютикал Гмбх, Коли Фармасьютикал Груп, Инк. filed Critical Коли Фармасьютикал Гмбх
Publication of EA200800943A1 publication Critical patent/EA200800943A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Abstract

Настоящее изобретение относится к способности некоторых олигонуклеотидов модифицировать профиль лигандов для TLR, таких как лиганды для TLR7, TLR8 и TLR9.The present invention relates to the ability of some oligonucleotides to modify the ligand profile for TLR, such as ligands for TLR7, TLR8 and TLR9.

EA200800943A 2005-09-27 2006-09-27 MODULATION OF TLR-MEDIATED IMMUNE RESPONSES WITH THE USE OF OLIGONUCLEOTIDE ADAPTERS EA200800943A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72098105P 2005-09-27 2005-09-27
PCT/US2006/037987 WO2007038720A2 (en) 2005-09-27 2006-09-27 Modulation of tlr-mediated immune responses using adaptor oligonucleotides

Publications (1)

Publication Number Publication Date
EA200800943A1 true EA200800943A1 (en) 2008-12-30

Family

ID=37900484

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800943A EA200800943A1 (en) 2005-09-27 2006-09-27 MODULATION OF TLR-MEDIATED IMMUNE RESPONSES WITH THE USE OF OLIGONUCLEOTIDE ADAPTERS

Country Status (9)

Country Link
EP (1) EP1928500A2 (en)
JP (1) JP2009510096A (en)
KR (1) KR20080059595A (en)
CN (1) CN101340931A (en)
AU (1) AU2006294528A1 (en)
BR (1) BRPI0616770A2 (en)
CA (1) CA2623764A1 (en)
EA (1) EA200800943A1 (en)
WO (1) WO2007038720A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ES2628744T3 (en) 1998-05-22 2017-08-03 Ottawa Hospital Research Institute Methods and products to induce immunity in mucous membranes
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
BR0315810A (en) 2002-10-29 2005-09-13 Coley Pharmaceutical Group Ltd Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
WO2007024707A2 (en) 2005-08-22 2007-03-01 The Regents Of The University Of California Tlr agonists
EP1934239B8 (en) * 2005-10-12 2015-11-04 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
AU2007257423B8 (en) 2006-05-31 2012-02-16 The Regents Of The University Of California Purine analogs
US8377898B2 (en) 2006-10-12 2013-02-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
EP2510946B1 (en) 2007-02-07 2015-08-05 The Regents of The University of California Conjugates of synthetic tlr agonists and uses therefor
JP5753382B2 (en) * 2007-11-06 2015-07-22 アディウティーダ ファーマシューティカルズ ゲーエムベーハー Immunostimulatory oligoribonucleotide analogs containing modified oligophosphate groups
EP3087988A3 (en) 2008-10-06 2017-03-01 Idera Pharmaceuticals, Inc. Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
CA2752074A1 (en) 2009-02-11 2010-08-19 The Regents Of The University Of California Toll-like receptor modulators and treatment of diseases
CN102612561A (en) 2009-06-01 2012-07-25 艾德拉药物股份有限公司 Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (iro) antagonists of tlr7 and tlr9
JP6026405B2 (en) 2010-04-30 2016-11-16 テロルメディクス エセアー Phospholipid drug analogues
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
WO2019160866A2 (en) * 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
US11504425B2 (en) 2019-02-26 2022-11-22 Wayne State University Amphiphilic oligodeoxynucleotide conjugates as adjuvant enhancers
CN114588130B (en) * 2020-11-20 2023-07-04 四川好医生攀西药业有限责任公司 Adhesive bandage containing periplaneta americana active ingredient and preparation method thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022809A2 (en) * 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
EP1499187B1 (en) * 2002-04-04 2015-06-17 Zoetis Belgium S.A. Immunostimulatory g,u-containing oligoribonucleotides
WO2005016235A2 (en) * 2003-04-14 2005-02-24 The Regents Of The University Of California Combined use of impdh inhibitors with toll-like receptor agonists
JP2007524615A (en) * 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー Low molecular weight Toll-like receptor (TLR) antagonist
NZ545536A (en) * 2003-09-05 2010-04-30 Anadys Pharmaceuticals Inc TLR7 ligands for the treatment of hepatitis C
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
US20050239733A1 (en) * 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides

Also Published As

Publication number Publication date
BRPI0616770A2 (en) 2011-06-28
AU2006294528A1 (en) 2007-04-05
WO2007038720A3 (en) 2007-06-21
WO2007038720A2 (en) 2007-04-05
KR20080059595A (en) 2008-06-30
EP1928500A2 (en) 2008-06-11
CN101340931A (en) 2009-01-07
CA2623764A1 (en) 2007-04-05
JP2009510096A (en) 2009-03-12

Similar Documents

Publication Publication Date Title
EA200800943A1 (en) MODULATION OF TLR-MEDIATED IMMUNE RESPONSES WITH THE USE OF OLIGONUCLEOTIDE ADAPTERS
CY1119567T1 (en) Therapeutic Peptides
EA200801045A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNE DISORDERS
EA201300242A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED ACYLANILIDES
MX361862B (en) Compositions and methods comprising a lipolytic enzyme variant.
TR201708567T4 (en) The use of sigma ligands in bone cancer pain.
WO2015010009A3 (en) Compositions and methods comprising a lipolytic enzyme variant
TW200732382A (en) Siloxane encapsulants
EA200970471A1 (en) MICROORGANISMS OR THEIR FRACTIONS ENSURING THE ACTIVATION OF CELLULAR IMMUNITY AGAINST CARBOHYDRATES
EA201070247A1 (en) PROTEAS INHIBITORS
TW200716624A (en) Compounds for modulating TRPV3 function
PH12016500137B1 (en) Afucosylated anti-fgfr2iiib antibodies
BRPI0618473A2 (en) combinations and methods of using an immunomodulatory oligodeoxynucleotide
MX343042B (en) Bicyclic heteroaryl compounds.
ATE488232T1 (en) P53 ACTIVATE BENZOYL UREA AND BENZOYLTHIOUREA COMPOUNDS
EA201201650A1 (en) HUMAN BINDING MOLECULES THAT HAVE KILLING ACTIVITY AGAINST STAFILOCCUS AND THEIR APPLICATION
EA201591474A1 (en) METHOL MODIFYING ENZYME MODULATORS, COMPOSITIONS AND THEIR APPLICATION
EA201790267A1 (en) NEW KINAZ MODULATORS
EA201490563A1 (en) ANTI-SMALL OLIGONUCLEOTIDE FOR THE TREATMENT OF CONGENITAL LEAVER AMAUROSIS
MX360301B (en) Boron-containing small molecules as anti-inflammatory agents.
WO2008033432A3 (en) Immune modulation by chemically modified ribonucleosides and oligoribonucleotides
JO2788B1 (en) Amidophenoxyindazoles useful as inhibitors of c-met
TW200509892A (en) Novel aminobenzophenone compounds
BR112013020259A2 (en) osteoarthritis and pain treatment
MY178288A (en) Complex containing oligonucleotide having immunopotentiating activity and use thereof